Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management

CX Ma, XN Ma, CH Guan, YD Li, D Mauricio… - Cardiovascular …, 2022 - Springer
Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2
diabetes mellitus (T2DM), particularly in low-and middle-income countries. To effectively …

The platelet lifeline to cancer: challenges and opportunities

M Haemmerle, RL Stone, DG Menter… - Cancer cell, 2018 - cell.com
Besides their function in limiting blood loss and promoting wound healing, experimental
evidence has highlighted platelets as active players in all steps of tumorigenesis including …

[HTML][HTML] Antiplatelet therapy after percutaneous coronary intervention

DJ Angiolillo, M Galli, JP Collet, A Kastrati… - …, 2022 - ncbi.nlm.nih.gov
Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …

[HTML][HTML] Editor's choice--European Society for Vascular Surgery (ESVS) 2024 clinical practice guidelines on the management of asymptomatic lower limb peripheral …

J Nordanstig, CA Behrendt, I Baumgartner… - European Journal of …, 2024 - Elsevier
BIOTRONIK's First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter
vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularisation of …

Homocysteine‐lowering interventions for preventing cardiovascular events

AJ Marti-Carvajal, I Sola, D Lathyris… - Cochrane database of …, 2017 - cochranelibrary.com
Background Cardiovascular disease, which includes coronary artery disease, stroke and
peripheral vascular disease, is a leading cause of death worldwide. Homocysteine is an …

[HTML][HTML] Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review

G Agnelli, JJF Belch, I Baumgartner, P Giovas… - Atherosclerosis, 2020 - Elsevier
Background and aims It is unclear whether improvements in the detection/treatment of
peripheral artery disease (PAD) affect overall survival and morbidity. We undertook a …

Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis

F Andreotti, B Rocca, S Husted, RA Ajjan… - European heart …, 2015 - academic.oup.com
Contemporary medicine is shifting towards person rather than disease-oriented care. 1 With
increasing life expectancy and the ageing of baby boomers, the proportion over 60 years is …

Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes: a post hoc analysis of the randomized GLOBAL LEADERS trial

M Tomaniak, P Chichareon, Y Onuma… - JAMA …, 2019 - jamanetwork.com
Importance The role of aspirin as part of antiplatelet regimens in acute coronary syndromes
(ACS) needs to be clarified in the context of newer potent P2Y12 antagonists. Objective To …

The relationship between atrial fibrillation and coronary artery disease: Understanding common denominators

M Mekhael, N Marrouche, AH El Hajjar… - Trends in cardiovascular …, 2022 - Elsevier
Atrial fibrillation (AF) and coronary artery disease (CAD) are highly prevalent cardiovascular
conditions. The coexistence of both diseases is common as they share similar risk factors …

[HTML][HTML] Peripheral arterial disease (PAD)–A challenging manifestation of atherosclerosis

J Nordanstig, CA Behrendt, AW Bradbury… - Preventive …, 2023 - Elsevier
The diagnosis of peripheral arterial disease (PAD) is not always evident as symptoms and
signs may show great variation. As all grades of PAD are linked to both an increased risk for …